Celldex Q2 net loss $73.5M; barzolvolimab Phase 3 CSU topline data expected Sept/Oct 2026

Celldex Therapeutics, Inc.

Net loss of $73.5M ($0.94/share) vs $56.6M in Q2 2025; no material revenue.
Cash $717.6M after $323.8M public offering; runway through 2028.
Barzolvolimab Phase 3 CSU enrolled 1,939 patients; topline data Sept/Oct 2026; BLA planned 2027.
Phase 2 prurigo nodularis study failed primary endpoints; discontinued.
CDX-622 Phase 1 showed rapid tryptase reduction; asthma POM study ongoing; expanding into allergic rhinitis and food allergy.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.